Lakeland PeptidesPeptide therapy, explained · Lakeland & Polk County, FL

Peptide library

Semaglutide: What Lakeland Readers Should Know

Also known as: Ozempic, Wegovy, Rybelsus, GLP-1

Not reviewed by a licensed provider. Read our disclaimer

Last updated

At a glance

Type
GLP-1 receptor agonist
Human evidence
FDA-approved Approved by the FDA for specific uses after large clinical trials.
FDA status
FDA-approved (Ozempic, Rybelsus, Wegovy); compounded and online versions are not (as of October 1, 2026)
How it is given
Injection under the skin, or a tablet by mouth

Semaglutide is the active ingredient in Ozempic, Rybelsus and Wegovy, prescription medicines made by Novo Nordisk. Large trials stand behind it, which is not true of most drugs discussed as “peptide therapy.” This page is general information, not advice for your situation.

What it is and how it works

Semaglutide is a lab-made version of GLP-1, a hormone your gut releases after you eat. It is a 94% match to natural GLP-1, switches on the same receptor, and lasts about a week in the body.1

According to the Wegovy label, it lowers how many calories people eat, likely by acting on appetite, and the weight lost is more fat than lean tissue. It also slows how fast food leaves the stomach, which can change how some pills are absorbed.1

FDA-approved forms are a weekly injection under the skin (Ozempic, Wegovy) and a daily tablet (Rybelsus, Ozempic tablets, Wegovy tablets). Tablets are taken on an empty stomach with a little water.2 Doses are raised step by step. This site does not give dosing.

What the research shows (and where evidence is weak)

Semaglutide has been tested in large randomized controlled trials, where people are assigned by chance to the drug or a placebo (a dummy treatment).

  • Weight. STEP 1 followed 1,961 adults with obesity, or overweight plus a weight-related condition, who did not have diabetes. After 68 weeks, average weight fell 14.9% on semaglutide versus 2.4% on placebo. About half on semaglutide (50.5%) lost at least 15% of their weight, compared with 4.9% on placebo.3 Everyone in these trials also got diet and exercise counseling.1
  • Heart events. SELECT followed 17,604 adults with heart disease and overweight or obesity, but no diabetes, for about 3 years. A heart attack, stroke or heart-related death happened to 6.5% on semaglutide versus 8.0% on placebo.4 Heart-related death on its own was not clearly lowered. The label says an effect on heart failure has not been shown.1
  • Kidneys. In 3,533 people with type 2 diabetes and kidney disease, Ozempic lowered the combined risk of serious kidney decline, kidney failure or heart-related death.5

Where the evidence is weaker:

  • Stopping. In STEP 4, people who switched to placebo after 20 weeks regained weight (+6.9%), while those who stayed on the drug kept losing (−7.9%).6 In an exploratory follow-up of 327 STEP 1 participants, people regained about two-thirds of the weight they had lost in the year after stopping. Most gains in blood pressure, blood sugar and similar measures faded.7
  • Muscle. Some of the weight lost is “lean mass.” That measure includes organs, water and bone, not only muscle. Studies report lean mass making up anywhere from about 15% to 60% of the weight lost, and few studies measure strength directly. Older adults are the main group of concern.8
  • Who paid. The manufacturer funded the main trials, which tested only FDA-approved products, not compounded or online versions.34

FDA and regulatory status

As of labels revised between January and June 2026, semaglutide is FDA-approved as:

  • Ozempic (injection): for blood-sugar control in adults with type 2 diabetes, and to lower heart-event risk or kidney-related risks in adults with type 2 diabetes and heart or kidney disease.5
  • Rybelsus and Ozempic tablets: for blood-sugar control in adults with type 2 diabetes, and to lower heart-event risk in those at high risk.2
  • Wegovy (injection and tablets): with diet and activity, for long-term weight reduction in adults with obesity, or with overweight plus a weight-related condition. The injection is also approved for children 12 and older with obesity. Wegovy is also approved to lower heart-event risk in adults with heart disease and obesity or overweight. The injection is labeled for a fatty-liver disease called MASH with moderate to advanced scarring under “accelerated approval,” which means continued approval may depend on a confirming trial.1

Compounding. Semaglutide injections were in national shortage from 2022. FDA declared the shortage resolved on February 21, 2025, and the grace periods for compounders ended in spring 2025.9 As of April 2026, FDA said pharmacies may not regularly make “essentially copies” of an approved drug, and that semaglutide mixed with vitamin B12 can count as a copy.9 On April 30, 2026, FDA proposed barring outsourcing facilities (large-scale compounders) from making semaglutide from bulk powder.10 As of November 13, 2026, we did not find a final FDA decision on that proposal. Check FDA’s announcement for updates.10 Compounded drugs are not FDA-approved.9 Our guide to compounded vs. FDA-approved peptides explains the difference.

Online and “research” products. FDA says semaglutide sodium and semaglutide acetate are different ingredients from the approved drug, with no known lawful basis for compounding. It also reports counterfeit Ozempic in the U.S. and has warned sellers of “research purposes” semaglutide sold to consumers.11 See the risks of research-chemical peptides.

Sport. The U.S. Anti-Doping Agency says GLP-1 medicines are not prohibited in sport.12

Common side effects and safety

Stomach and bowel effects are the most common. In the Wegovy weight trials, nausea affected 44% of people versus 16% on placebo, diarrhea 30% versus 16%, vomiting 24% versus 6%, and constipation 24% versus 11%.1 In SELECT, 16.6% stopped the drug because of side effects, versus 8.2% on placebo.4

All semaglutide products carry a boxed warning, FDA’s strongest kind. Semaglutide caused thyroid C-cell tumors in rodents. Whether it does so in people is unknown. It should not be used by anyone with a personal or family history of medullary thyroid cancer or a condition called MEN 2.1

Other label warnings include pancreatitis (an inflamed pancreas), gallbladder problems, low blood sugar with insulin or certain diabetes pills, kidney injury from dehydration, severe stomach problems, allergic reactions, a faster heart rate, eye complications in type 2 diabetes, and breathing stomach contents into the lungs during anesthesia.1

In the heart trial, adults 75 and older had more hip and pelvis fractures on Wegovy. The label also says to stop at least 2 months before a planned pregnancy.1 In 2025, Europe’s drug regulator listed NAION, a sudden optic-nerve problem that affects vision, as a very rare side effect, at about 1 extra case per 10,000 years of use.13 The U.S. labels reviewed do not mention it.

FDA reports about 990 adverse-event reports linked to compounded semaglutide, plus dosing mistakes, some needing hospital care. A report does not prove the drug caused the problem.11

Typical cost range

As of November 12, 2026, Novo Nordisk listed these self-pay prices for Wegovy:14

  • Wegovy pills: $149 to $299 a month, depending on strength.
  • Wegovy pens: $349 a month for most strengths and $399 for the high-dose pen. New patients pay $199 a month for the first 2 fills of the two lowest strengths, through December 31, 2026.
  • List price: $1,349.02 per package before any discount.

Money paid this way does not count toward your insurance deductible.14 Offers can change. Since July 1, 2026, a temporary Medicare program called the GLP-1 Bridge has given eligible Part D members certain GLP-1 drugs for a $50 copay. It runs through December 31, 2027.15

Self-pay prices for Ozempic and Rybelsus, and local clinic prices for compounded semaglutide, were not part of this research. Prices vary between pharmacies and clinics. Ask any provider for a written price breakdown before you start. Our cost guide and insurance, HSA and FSA guide cover what to ask.

Questions to ask a provider

  • Which semaglutide product and approved use fit my health history?
  • Is this a brand-name product or a compounded one? If compounded, why, and which state-licensed pharmacy makes it?
  • How will you check thyroid, pancreas, gallbladder and kidney risks first?
  • How do I reach you if side effects get worse?
  • What is the plan if I stop?
  • Does my insurance or Medicare cover it, and what is the full monthly cost?

Footnotes

  1. Novo Nordisk. WEGOVY (semaglutide) injection and tablets: prescribing information. Revised June 2026. Accessed November 2026. https://www.novo-pi.com/wegovy.pdf ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9

  2. Novo Nordisk. RYBELSUS and OZEMPIC (semaglutide) tablets: prescribing information. Revised January 2026. Accessed November 2026. https://www.novo-pi.com/rybelsus.pdf ↩ ↩2

  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183 ↩ ↩2

  4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. https://doi.org/10.1056/NEJMoa2307563 ↩ ↩2 ↩3

  5. Novo Nordisk. OZEMPIC (semaglutide) injection: prescribing information. Revised May 2026. Accessed November 2026. https://www.novo-pi.com/ozempic.pdf ↩ ↩2

  6. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. https://doi.org/10.1001/jama.2021.3224 ↩

  7. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://doi.org/10.1111/dom.14725 ↩

  8. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27. https://doi.org/10.1111/dom.15728 ↩

  9. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Content current as of April 1, 2026. Accessed November 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize ↩ ↩2 ↩3

  10. U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. Press release. April 30, 2026. Accessed November 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list ↩ ↩2

  11. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. Accessed November 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss ↩ ↩2

  12. U.S. Anti-Doping Agency. Weight loss drugs: what athletes need to know about GLP-1s. Accessed November 2026. https://www.usada.org/spirit-of-sport/weight-loss-drugs-glp-1s/ ↩

  13. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. June 6, 2025. Accessed November 2026. https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy ↩

  14. Novo Nordisk. NovoCare: Price your Wegovy. Accessed November 12, 2026. https://www.novocare.com/obesity/products/wegovy.html ↩ ↩2

  15. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. Last modified July 13, 2026. Accessed November 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge ↩

Frequently asked questions

Is semaglutide the same as Ozempic and Wegovy?

Semaglutide is the active ingredient. Ozempic and Rybelsus are approved for type 2 diabetes and related heart or kidney risks. Wegovy is approved for long-term weight management and for lowering heart risk in some people. Each brand has its own approved uses.

Is compounded semaglutide the same as the brand-name product?

No. Compounded drugs are not FDA-approved. The national shortage that allowed wide compounding ended in February 2025. FDA has also warned about dosing mistakes, salt forms and counterfeit products.

What happens if I stop taking semaglutide?

In trials, most people regained much of the weight they had lost within a year of stopping. Improvements in blood pressure and blood sugar also tended to fade.

How much does semaglutide cost without insurance?

As of November 2026, Novo Nordisk listed Wegovy pills at $149 to $299 a month and pens at $349 to $399 a month, with a lower introductory price for new patients. These offers can change.

Related goals

Questions? Talk to a licensed provider

See a free list of top rated clinics in Lakeland and Polk County, with their phone numbers and Google reviews. No one will call you.

Find a top rated provider
Find a top rated provider today